Clinical observation of recombinant human epidermal growth factor in treatment of recurrent oral ulcer in elderly patients
10.3969/j.issn.1005-1678.2017.04.014
- VernacularTitle:重组人表皮生长因子治疗老年反复发作性口腔溃疡的临床疗效
- Author:
Jingli LI
;
Xihui SHI
;
Xubin CHEN
- Keywords:
recombinant human epidermal growth factor;
elderly patients;
recurrent oral ulcers
- From:
Chinese Journal of Biochemical Pharmaceutics
2017;37(4):43-45
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical efficacy of recombinant human epidermal growth factor in the treatment of recurrent oral ulcers in elderly patients.Methods 82 cases of elderly patients in our hospital in the treatment of recurrent oral ulcer were selected,41 cases in the control group,the conventional western medicine treatment,41 cases of the study group,recombinant human epidermal growth factor in treatment before and after treatment,blood determination of immune status,clinical efficacy and adverse reactions of comparison were performed at one-year follow-up.Results the effective rate of treatment group is lower than 78.05％of the effective rate of treatment group 95.12％,study group 3,6 and 12 months recurrence rate(4.88％,7.32％,7.32％)than in the control group the recurrence rate(19.51％,24.39％,29.27％),the study group after the treatment of CD3+ and CD4+/CD8+ and NK were higher than the control group,the CD8+ level is lower than the control group(P<0.05),the two groups had no serious adverse reaction.Conclusion recombinant human epidermal growth factor is effective in the treatment of oral ulcer.
